$GRTS
Gritstone bio Inc

2019 Q2 Form 10-Q Financial Statement

#000156459019031362 Filed on August 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2 2018 Q1
Revenue $1.150M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.840M $2.810M $2.040M
YoY Change 72.24%
% of Gross Profit
Research & Development $18.53M $12.69M $11.40M
YoY Change 46.02%
% of Gross Profit
Depreciation & Amortization $1.090M $970.0K $910.0K
YoY Change 12.37% 14.12%
% of Gross Profit
Operating Expenses $23.36M $15.50M $13.44M
YoY Change 50.71%
Operating Profit -$22.21M -$15.50M -$13.44M
YoY Change 43.28% 97.48% 96.36%
Interest Expense $1.042M $31.00K $63.00K
YoY Change 3261.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$21.17M -$15.47M -$13.38M
YoY Change 36.85%
Income Tax
% Of Pretax Income
Net Earnings -$21.17M -$15.47M -$13.38M
YoY Change 36.83% 98.63% 97.64%
Net Earnings / Revenue -1841.04%
Basic Earnings Per Share
Diluted Earnings Per Share -$630.4K -$548.0K -$474.0K
COMMON SHARES
Basic Shares Outstanding 35.72M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q2 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $181.2M $64.50M
YoY Change 180.93%
Cash & Equivalents $107.7M $38.53M $30.73M
Short-Term Investments $73.50M $26.90M
Other Short-Term Assets $389.0K $2.400M
YoY Change -83.79%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $184.7M $66.90M
YoY Change 176.08%
LONG-TERM ASSETS
Property, Plant & Equipment $18.97M $27.50M
YoY Change -31.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $500.0K
YoY Change
Other Assets $100.0K $1.500M
YoY Change -93.33%
Total Long-Term Assets $43.48M $29.10M
YoY Change 49.43%
TOTAL ASSETS
Total Short-Term Assets $184.7M $66.90M
Total Long-Term Assets $43.48M $29.10M
Total Assets $228.2M $96.00M
YoY Change 137.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.253M $2.700M
YoY Change 94.56%
Accrued Expenses $1.803M $2.500M
YoY Change -27.88%
Deferred Revenue $5.498M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.07M $5.200M
YoY Change 247.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $10.50M
YoY Change -100.0%
Other Long-Term Liabilities $27.70M $1.600M
YoY Change 1631.25%
Total Long-Term Liabilities $27.70M $12.10M
YoY Change 128.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.07M $5.200M
Total Long-Term Liabilities $27.70M $12.10M
Total Liabilities $45.80M $17.30M
YoY Change 164.75%
SHAREHOLDERS EQUITY
Retained Earnings -$165.7M
YoY Change
Common Stock $17.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $182.4M $78.67M $84.29M
YoY Change
Total Liabilities & Shareholders Equity $228.2M $96.00M
YoY Change 137.69%

Cashflow Statement

Concept 2019 Q2 2018 Q2 2018 Q1
OPERATING ACTIVITIES
Net Income -$21.17M -$15.47M -$13.38M
YoY Change 36.83% 98.63% 97.64%
Depreciation, Depletion And Amortization $1.090M $970.0K $910.0K
YoY Change 12.37% 14.12%
Cash From Operating Activities -$18.41M -$12.01M -$15.06M
YoY Change 53.29% -7.9%
INVESTING ACTIVITIES
Capital Expenditures -$2.250M -$1.170M $1.692M
YoY Change 92.31% -68.38%
Acquisitions
YoY Change
Other Investing Activities $24.03M $12.75M $7.470M
YoY Change 88.47% 20.62%
Cash From Investing Activities $21.78M $11.58M $5.778M
YoY Change 88.08% 68.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $69.70M $9.000K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 69.79M 8.230M 9.000K
YoY Change 748.0% 82200.0%
NET CHANGE
Cash From Operating Activities -18.41M -12.01M -15.06M
Cash From Investing Activities 21.78M 11.58M 5.778M
Cash From Financing Activities 69.79M 8.230M 9.000K
Net Change In Cash 73.16M 7.800M -9.273M
YoY Change 837.95% -226.62%
FREE CASH FLOW
Cash From Operating Activities -$18.41M -$12.01M -$15.06M
Capital Expenditures -$2.250M -$1.170M $1.692M
Free Cash Flow -$16.16M -$10.84M -$16.75M
YoY Change 49.08% 16.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
783000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
94000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-15472000
us-gaap Net Income Loss
NetIncomeLoss
-39181000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
001-38663
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
474859534
dei Entity Address Address Line1
EntityAddressAddressLine1
5858 Horton Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
California
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
871-6100
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107728000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52183000
CY2019Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
73511000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
100927000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3458000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4526000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
184697000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
157636000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18966000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29494000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21309000
CY2019Q2 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2700000
CY2018Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2428000
CY2019Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
508000
CY2019Q2 us-gaap Assets
Assets
228180000
CY2018Q4 us-gaap Assets
Assets
189558000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5253000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4825000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2621000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3951000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1803000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
992000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2890000
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5498000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5340000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18065000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15108000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1353000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12000
CY2018Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
10490000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16919000
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
10818000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13473000
CY2019Q2 us-gaap Liabilities
Liabilities
45802000
CY2018Q4 us-gaap Liabilities
Liabilities
40436000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
17000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
348021000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
275593000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
76000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165736000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126402000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-85000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
182378000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
149122000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
228180000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189558000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35654631
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28823130
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35654631
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28823130
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1150000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2497000
CY2019Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18529000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12689000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34428000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24090000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4835000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2814000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9212000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4852000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
23364000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
15503000
us-gaap Operating Expenses
OperatingExpenses
43640000
us-gaap Operating Expenses
OperatingExpenses
28942000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22214000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15503000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41143000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28942000
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1042000
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
31000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1962000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-21172000
us-gaap Net Income Loss
NetIncomeLoss
-28848000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
58000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
161000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
43000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21163000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15414000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
84286000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.57
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
362000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39020000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28805000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-12.62
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33582844
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2353337
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31273696
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2285906
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
132222000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69709000
CY2019Q2 grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
17000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
276000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1317000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8928000
CY2018Q2 grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
38000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2018Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
36000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
78672000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69709000
grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
34000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2324000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
97282000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8928000
grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
60000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
grts Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
13000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
36000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1137000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2130000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1882000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
970000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
180000
us-gaap Share Based Compensation
ShareBasedCompensation
2324000
us-gaap Share Based Compensation
ShareBasedCompensation
1173000
us-gaap Operating Lease Cost
OperatingLeaseCost
2837000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-268000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-415000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1329000
grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
1312000
grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
-765000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-206000
grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-1293000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2497000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37538000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27066000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
16012000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
44050000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
20220000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4831000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2857000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23207000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17363000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70432000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
556000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
779000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
8992000
grts Increase Decrease In Deposit And Other Assets Current
IncreaseDecreaseInDepositAndOtherAssetsCurrent
272000
grts Increase Decrease In Deposit And Other Assets Current
IncreaseDecreaseInDepositAndOtherAssetsCurrent
-74000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-867000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-177000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-434000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69876000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8237000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
55545000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1466000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53175000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39999000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108720000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38533000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2775000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
247000
grts Deferred Financing Costs Included In Accrued Liabilities And Accounts Payable
DeferredFinancingCostsIncludedInAccruedLiabilitiesAndAccountsPayable
345000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of revenue and expenses in the condensed financial statements and accompanying notes during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical and preclinical study trial accruals, fair value of assets and liabilities the present value of lease liabilities and the corresponding right-of-use assets (&#8220;ROU assets&#8221;), and the fair value of common stock and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
108720000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53175000
CY2019Q2 grts Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
169185000
CY2019Q2 grts Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
76000
CY2019Q2 grts Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
169261000
CY2019Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
95242000
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
69700000
CY2018Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1449
CY2019Q2 grts Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
181700000
CY2018Q4 grts Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
153100000
CY2017Q4 grts Capital Expenditure Due But Not Yet Received
CapitalExpenditureDueButNotYetReceived
1200000
CY2019Q2 us-gaap Restricted Cash
RestrictedCash
992000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
992000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
74019000
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
48195000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
100927000
CY2018Q4 grts Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
149122000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2019Q2 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3742000
CY2019Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27000000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36245000
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8034000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6751000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000
CY2018Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1493000
CY2019Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
65000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
122000
CY2019Q2 us-gaap Lease Cost
LeaseCost
1558000
us-gaap Lease Cost
LeaseCost
2959000
us-gaap Operating Lease Payments
OperatingLeasePayments
1293000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
342000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1751000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5170000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4383000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3459000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
15979000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
34484000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10529000
CY2019Q2 grts Operating Lease Tenant Improvement Allowance
OperatingLeaseTenantImprovementAllowance
4146000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
19809000
CY2019Q2 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
1848000
CY2018Q4 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
1789000
CY2019Q2 us-gaap Prepaid Insurance
PrepaidInsurance
333000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
966000
CY2018Q4 us-gaap Prepaid Rent
PrepaidRent
860000
CY2019Q2 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
888000
CY2018Q4 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
462000
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
389000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
449000
CY2019Q2 us-gaap Security Deposit
SecurityDeposit
1055000
CY2018Q4 us-gaap Security Deposit
SecurityDeposit
632000
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
992000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
992000
CY2019Q2 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
553000
CY2018Q4 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
554000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
100000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2018Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
445000
CY2019Q2 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
998000
CY2018Q4 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
252000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
805000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
295000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
18813000
grts Contract With Customer Liability Addition
ContractWithCustomerLiabilityAddition
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-2497000
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
16316000
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsAuthorized
1160000
us-gaap Preferred Stock Redemption Terms
PreferredStockRedemptionTerms
A redemption event will only occur upon the liquidation or winding up of the Company, a greater than 50% change in control, or the sale of substantially all of the assets of the Company.
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of common stock are generally entitled to one vote per share on all matters to be voted upon by the stockholders of the Company.
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0209
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0250
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0265
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.89
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.62
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.37
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2695110
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted
992048
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
152585
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Repurchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRepurchased
11680
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3027327
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2429859
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
992048
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
230624
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
152585
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3038698
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
784201
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2987908
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.31
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.76
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.57
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.33
grts Share Based Compensation Arrangements By Share Based Payment Award Options Repurchased In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice
0.35
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.55
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.48
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.15
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y2M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M15D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
25646000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13347000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
6053000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
14176000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1317000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
819000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2324000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1173000
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3159936
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20491939
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3159936
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20491939

Files In Submission

Name View Source Status
0001564590-19-031362-index-headers.html Edgar Link pending
0001564590-19-031362-index.html Edgar Link pending
0001564590-19-031362.txt Edgar Link pending
0001564590-19-031362-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
grts-10q_20190630.htm Edgar Link pending
grts-20190630.xml Edgar Link completed
grts-20190630.xsd Edgar Link pending
grts-20190630_cal.xml Edgar Link unprocessable
grts-20190630_def.xml Edgar Link unprocessable
grts-20190630_lab.xml Edgar Link unprocessable
grts-20190630_pre.xml Edgar Link unprocessable
grts-ex311_6.htm Edgar Link pending
grts-ex312_8.htm Edgar Link pending
grts-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending